
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is positioned to potentially disrupt the market and gain a significant market share with the positive results and unique mechanism of action of Roluperidone in the treatment of negative symptoms in schizophrenia. Furthermore, the company's dedicated focus on CNS diseases, with a strong pipeline including other promising drug candidates such as Seltorexant, indicates a strong growth potential. With promising clinical data and a successful asset, Minerva Neurosciences has the potential to deliver significant financial returns to investors in the long term.
Bears say
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases. However, the company has faced challenges with its primary product candidate, roluperidone, failing to meet its primary endpoint in a Phase 3 trial and showing only numerical separation from placebo. Furthermore, there are concerns about the likelihood of positive symptom relapses and the potential for negative side effects with roluperidone as a monotherapy. These risks, combined with the limited market potential for a drug focused solely on treating negative symptoms in schizophrenia patients, lead to a negative outlook for Minerva Neurosciences's stock.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares